F. Hoffmann-La Roche — Genentech
Tracked across 6 events · 55 articles · First seen Dec 19, 2025 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
F. Hoffmann-La Roche — Genentech>>>, a member of the Roche Group, announced that the United States — Food and Drug Administration>>> (FDA) has accepted its New Drug Application (NDA) for giredestrant under Priority Review. Giredestrant…
Impact: As a member of the Roche Group, F. Hoffmann-La Roche — Genentech>>> developed giredestrant and had its New Drug Application accepted by the United States — Food and Drug Administration>>> for priority review, indicating potential for a new standard-of-care in breast cancer treatment.
Jun 02, 2026 · 6 articles
Tech
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, announced new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association. The data highlights significant…
Impact: F. Hoffmann-La Roche — Genentech announced positive Phase II clinical trial data for its obesity drugs, enicepatide and petrelintide, which could significantly strengthen its product portfolio and market position in the obesity treatment sector. The company is advancing both drugs to Phase III development and initiating a combination trial.
May 27, 2026 · 19 articles
Regulatory
Impact: F. Hoffmann-La Roche — Genentech, Roche's US unit, is one of the nine major pharmaceutical companies that signed deals with the Donald Trump administration to reduce drug prices.
Dec 19, 2025 · 7 articles
Business
MiNK Therapeutics, a genomic medicine company, has announced it is exploring strategic alternatives to maximize value for its stakeholders. The company has retained Raymond James Financial as its financial advisor to assist in evaluating options…
Impact: F. Hoffmann-La Roche — Genentech has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
Business
Impact: Gavin Barnard previously held senior leadership roles at F. Hoffmann-La Roche — Genentech, contributing to his extensive biopharma experience.
Apr 16, 2026 · 6 articles
100
United States — Food and Drug Administration accepted New Drug Application F. Hoffmann-La Roche — GenentechGenentech's Giredestrant...
90
F. Hoffmann-La Roche — Genentech announced data presentation American Diabetes AssociationGenentech Presents...
90
F. Hoffmann-La Roche — Genentech presented Phase II dataGenentech Presents...
90
F. Hoffmann-La Roche — Genentech announced acceptanceGenentech's Giredestrant...
80
F. Hoffmann-La Roche — Genentech initiated combination trialGenentech Presents...
NEWSDESK
Track F. Hoffmann-La Roche — Genentech live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard